Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11864172 | 1.00 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10706430 | 1.00 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27387712 | 0.97 | TSHR (0.46) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL215848 | 0.97 | TSHR (0.46) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29405565 | 0.97 | TSHR (0.46) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11818909 | 0.95 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27491899 | 0.95 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL10779050 | 0.95 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27476174 | 0.95 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27524236 | 0.95 | TSHR (0.45) | TSHRNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111892514-A | Method for preparing adiponitrile by direct hydrocyanation of butadiene | 阳泉煤业（集团）有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| US-8772527-B2 | Process for isomerization of cis-2-pentenenitrile to 3-pentenenitriles | BASF SE (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130289299-A1 | Process for Isomerization of CIS-2-Pentenenitrile to 3-Pentenenitriles | BASF SE (DE) | 2013-10-31 | — | — | US | disclosed |
| US-8530690-B2 | Process for isomerizing CIS-2-pentenenitrile to 3-pentenenitriles | BASF SE (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20110288326-A1 | PROCESS FOR ISOMERIZING CIS-2-PENTENENITRILE TO 3-PENTENENITRILES | BASF SE (DE) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288326-A1 | PROCESS FOR ISOMERIZING CIS-2-PENTENENITRILE TO 3-PENTENENITRILES | PARN, CPNE4, AAAS | TSHR 3145/4885NPC1 3583/4885RAB9A 1803/4885 |
| US-20130289299-A1 | Process for Isomerization of CIS-2-Pentenenitrile to 3-Pentenenitriles | PORCN, PIN1, ORAI2 | TSHR 4507/4885NPC1 2807/4885RAB9A 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.